Pfizer Inc. and EMD Serono, Merck KHaA’s biopharmaceutical arm in the United States and Canada, recently announced that Bavencio (avelumab) was approved by the U.S. Food and Drug Administration for intravenous use.
Pfizer and Merck have globally allied to enable each company to benefit from the other’s strengths and capabilities. Together, they are exploring the therapeutic potential of avelumab, an anti-PD-L1 antibody initially discovered and developed by Merck in Germany. The strategic alliance between the two allows for commercialization of avelumab with an international clinical program that will investigate whether avelumab works as a monotherapy.
As the biopharmaceutical arm of Merck, EMD Serono has developed cutting-edge science, innovative products and industry-leading patient support and access programs for more than 40 years. The 1,200-employee division has a headquarters in Massachusetts.
Its parent company, Merck, has 50,000 employees worldwide and is a leading science and technology company in the health care industry.